Citation: Ae. Stephen et al., Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo, P NAS US, 98(6), 2001, pp. 3214-3219
Authors:
Ha, TU
Segev, DL
Barbie, D
Masiakos, PT
Tran, TT
Dombkowski, D
Glander, M
Clarke, TR
Lorenzo, HK
Donahue, PK
Maheswaran, S
Citation: Tu. Ha et al., Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism, J BIOL CHEM, 275(47), 2000, pp. 37101-37109
Authors:
Masiakos, PT
MacLaughlin, DT
Maheswaran, S
Teixeira, J
Fuller, AF
Shah, PC
Kehas, DJ
Kenneally, MK
Dombkowski, DM
Ha, TU
Preffer, FI
Donahoe, PK
Citation: Pt. Masiakos et al., Human ovarian cancer, cell lines, and primary ascites cells express the human mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS, CLIN CANC R, 5(11), 1999, pp. 3488-3499
Authors:
Lee, MM
Seah, CC
Masiakos, PT
Sottas, CM
Preffer, FI
Donahoe, PK
Maclaughlin, DT
Hardy, MP
Citation: Mm. Lee et al., Mullerian-inhibiting substance type II receptor expression and function inpurified rat Leydig cells, ENDOCRINOL, 140(6), 1999, pp. 2819-2827